Based on daily access to fresh tissue Indivumed has established a comprehensive molecular drug test platform to understand pathway activity and drug effects in a large cohort of patient samples. The platform can be used to
- Understand heterogeneity of response between different patients
- To profile compounds in different tumor entities
- To prioritize drugs before clinical trials
- To discover or validate predictive biomarkers
The ultimate goal of this platform is to provide pharmaceutical companies with a tool for better understanding and predicting response of new compounds before moving into clinical trials.
The model includes
- Primary cells or intact tissue, short term cultivated, treated and analyzed directly after surgery
- Reference tissue collected intrasurgically according to Indivumed Standard
- Comprehensive clinical data to correlate findings with individual patient factors
- A comprehensive analytical platform that determines
- Viability
- Proliferation rate
- Apoptosis rate
- Pathway activity (total protein/phosphoprotein)
- Target expression
- DNA mutation status
- Proteomic profile
- Genomic profile
The choice of cell model depends on the scientific interest. Two cell models are offered, Primary Cells and Intact Tissue.
